| Year |
Citation |
Score |
| 2019 |
Mitchell LA, Yagiz K, Hofacre A, Viaud S, Munday AW, Espinoza FL, Mendoza D, Rodriguez-Aguirre ME, Bergqvist S, Haghighi A, Miner MV, Accomando WP, Burrascano C, Gammon D, Gruber HE, et al. PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models. Oncotarget. 10: 2252-2269. PMID 31040917 DOI: 10.18632/Oncotarget.26785 |
0.338 |
|
| 2018 |
Yagiz K, Rodriguez-Aguirre ME, Lopez Espinoza F, Montellano TT, Mendoza D, Mitchell LA, Ibanez CE, Kasahara N, Gruber HE, Jolly DJ, Robbins JM. A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models. Molecular Therapy Oncolytics. 8: 14-26. PMID 29322091 DOI: 10.1016/J.Omto.2017.12.001 |
0.431 |
|
| 2017 |
Mohanty SK, Yagiz K, Pradhan D, Luthringer DJ, Amin MB, Alkan S, Cinar B. STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer. Oncotarget. 8: 85997-86010. PMID 29156772 DOI: 10.18632/Oncotarget.20844 |
0.335 |
|
| 2017 |
Ready D, Yagiz K, Amin P, Yildiz Y, Funari V, Bozdag S, Cinar B. Mapping the STK4/Hippo signaling network in prostate cancer cell. Plos One. 12: e0184590. PMID 28880957 DOI: 10.1371/Journal.Pone.0184590 |
0.38 |
|
| 2017 |
Mohanty SK, Yagiz K, Luthringer L, Amin MB, Alkan S, Cinar B. Abstract 5707: STAT3 and STAT5a are potential therapeutic targets in castration-resistant prostate cancer Cancer Research. 77: 5707-5707. DOI: 10.1158/1538-7445.Am2017-5707 |
0.33 |
|
| 2017 |
Jolly D, Mitchell L, Yagiz K, Espinoza FL, Mendoza D, Munday A, Gruber H. Tmic-42. Toca 511 And 5-Fc Induces T Cell-Mediated Antitumor Immunity In A Mouse Glioma Model Which Is Enhanced By The Addition Of A Therapeutic Antibody Against Ctla-4 And Correlative With A Reduction In Memory T Regulatory Cells. Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.1030 |
0.338 |
|
| 2016 |
Yagiz K, Huang TT, Lopez Espinoza F, Mendoza D, Ibañez CE, Gruber HE, Jolly DJ, Robbins JM. Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models. Neuro-Oncology. PMID 27166379 DOI: 10.1093/Neuonc/Now089 |
0.352 |
|
| 2016 |
Mitchell L, Espinoza FL, Yagiz K, Mendoza D, Rodriguez-Aguirre M, Mitchell S, Jolly DJ, Robbins JM. Abstract 3212: Combining Toca 511 and 5-fluorocytosine with αPD-1 or αCTLA-4 antibody significantly reduces tumor burden compared to either checkpoint inhibitor alone or in combination in a subcutaneous mouse glioma model Cancer Research. 76: 3212-3212. DOI: 10.1158/1538-7445.Am2016-3212 |
0.456 |
|
| 2016 |
Rodriguez-Aguirre M, Yagiz K, Espinoza FL, Mendoza D, Huang TT, Ibanez C, Gruber HE, Jolly DJ, Robbins J. Abstract 1413: Treatment of mouse liver and brain colon cancer metastases with Toca 511 and 5-fluorocytosine for intratumoral production of 5-fluorouracil leads to increased survival, induction of antitumor immune responses, and reduction of MDSC Cancer Research. 76: 1413-1413. DOI: 10.1158/1538-7445.Am2016-1413 |
0.46 |
|
| 2016 |
Mitchell L, Yagiz K. Imst-01. Combining Toca 511 And 5-Fluorocytosine With Checkpoint Inhibitors Significantly Reduced Tumor Burden In A Mouse Model Of Glioma Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.358 |
0.368 |
|
| 2016 |
Yagiz K, Mendoza D, Rodriguez-Aguirre M, Espinoza FL, Ibañez CE, Gruber HE, Jolly DJ, Robbins JM. 205. Cytotoxic and Immunotherapeutic Effects of Toca 511 and 5-Fluorocytosine in an Intraperitoneal Model of Metastatic Colorectal Cancer Molecular Therapy. 24. DOI: 10.1016/S1525-0016(16)33014-3 |
0.453 |
|
| 2015 |
Yagiz K, Rodriguez-Aguirre ME, Espinoza FL, Martin B, Huang TT, Ibanez C, Ostertag D, Kasahara N, Gruber HE, Jolly DJ, Robbins JM. 531. Intravenous Delivery of Toca 511 Gene Therapy in Combination with 5-Fluorocytosine for Intratumoral Production of 5-Fluorouracil in a Colon Cancer Metastasis Model Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34140-5 |
0.414 |
|
| 2014 |
Candolfi M, Yagiz K, Wibowo M, Ahlzadeh GE, Puntel M, Ghiasi H, Kamran N, Paran C, Lowenstein PR, Castro MG. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1555-65. PMID 24501391 DOI: 10.1158/1078-0432.Ccr-13-2140 |
0.386 |
|
| 2012 |
Mineharu Y, Muhammad AK, Yagiz K, Candolfi M, Kroeger KM, Xiong W, Puntel M, Liu C, Levy E, Lugo C, Kocharian A, Allison JP, Curran MA, Lowenstein PR, Castro MG. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 9: 827-43. PMID 22996231 DOI: 10.1007/S13311-012-0144-7 |
0.432 |
|
| 2012 |
Candolfi M, King GD, Yagiz K, Curtin JF, Mineharu Y, Muhammad AK, Foulad D, Kroeger KM, Barnett N, Josien R, Lowenstein PR, Castro MG. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics. Neoplasia (New York, N.Y.). 14: 757-70. PMID 22952428 DOI: 10.1593/Neo.12794 |
0.395 |
|
| 2012 |
Collak FK, Yagiz K, Luthringer DJ, Erkaya B, Cinar B. Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1. The Journal of Biological Chemistry. 287: 23698-709. PMID 22619175 DOI: 10.1074/Jbc.M112.358713 |
0.374 |
|
| 2011 |
Candolfi M, Curtin JF, Yagiz K, Assi H, Wibowo MK, Alzadeh GE, Foulad D, Muhammad AK, Salehi S, Keech N, Puntel M, Liu C, Sanderson NR, Kroeger KM, Dunn R, et al. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia (New York, N.Y.). 13: 947-60. PMID 22028620 DOI: 10.1593/Neo.11024 |
0.443 |
|
| 2011 |
Candolfi M, Kroeger KM, Xiong W, Liu C, Puntel M, Yagiz K, Muhammad AG, Mineharu Y, Foulad D, Wibowo M, Assi H, Baker GJ, Lowenstein PR, Castro MG. Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. Anti-Cancer Agents in Medicinal Chemistry. 11: 729-38. PMID 21707497 DOI: 10.2174/187152011797378689 |
0.363 |
|
| 2011 |
Candolfi M, Yagiz K, Balasubramanian K, Puntel M, King GD, Mineharu Y, Muhammad AG, Foulad D, Barnett N, Kroeger KM, Lowenstein PR, Castro MG. Abstract 467: Circulating DNA released from brain tumors in response to conditional cytotoxic/immune stimulatory gene therapy induces activation of TLR9 on pDCs, leading to antitumor immunity Cancer Research. 71: 467-467. DOI: 10.1158/1538-7445.Am2011-467 |
0.422 |
|
| 2011 |
Candolfi M, Yagiz K, Assi H, Muhammad AG, Liu C, Foulad D, Alzadeh G, Pisera DA, Kroeger KM, Lowenstein PR, Castro MG. Abstract 3645: Glioma-derived factors induce the expansion of myeloid derived suppressor cells which mediate immune suppression and tumor progression Cancer Research. 71: 3645-3645. DOI: 10.1158/1538-7445.Am2011-3645 |
0.465 |
|
| 2010 |
Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, Tesarfreund M, Lee S, Debinski W, Sareen D, Svendsen CN, et al. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proceedings of the National Academy of Sciences of the United States of America. 107: 20021-6. PMID 21030678 DOI: 10.1073/Pnas.1008261107 |
0.394 |
|
| 2010 |
Xiong W, Candolfi M, Liu C, Muhammad AK, Yagiz K, Puntel M, Moore PF, Avalos J, Young JD, Khan D, Donelson R, Pluhar GE, Ohlfest JR, Wawrowsky K, Lowenstein PR, et al. Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. Plos One. 5: e11074. PMID 20552015 DOI: 10.1371/Journal.Pone.0011074 |
0.405 |
|
| 2010 |
Puntel M, Muhammad AK, Candolfi M, Salem A, Yagiz K, Farrokhi C, Kroeger KM, Xiong W, Curtin JF, Liu C, Bondale NS, Lerner J, Pechnick RN, Palmer D, Ng P, et al. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics. Journal of Virology. 84: 6007-17. PMID 20375153 DOI: 10.1128/Jvi.00398-10 |
0.38 |
|
| 2010 |
Muhammad AK, Puntel M, Candolfi M, Salem A, Yagiz K, Farrokhi C, Kroeger KM, Xiong W, Curtin JF, Liu C, Lawrence K, Bondale NS, Lerner J, Baker GJ, Foulad D, et al. Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Clinical Pharmacology and Therapeutics. 88: 204-13. PMID 20164833 DOI: 10.1038/Clpt.2009.260 |
0.366 |
|
| 2010 |
Lowenstein PR, Mineharu Y, King G, Candolfi M, Xiong W, Assi H, Yagiz K, Kroeger K, Bannykh S, Castro M. Comparison of intratumoral loading of Flt3L/TK-recruited dendritic cells and systemic vaccination with tumor-lysate loaded dendritic cells in the stringent syngeneic CNS1 rat glioma model: Effect of temozolomide on anti-glioma immunity. Journal of Clinical Oncology. 28: 2093-2093. DOI: 10.1200/Jco.2010.28.15_Suppl.2093 |
0.366 |
|
| 2010 |
Castro MG, Candolfi M, Yagiz K, Kroeger KM, Foulad D, AhlZadeh GE, Tesarfreund M, Lowenstein PR. Abstract 3825: Synergistic antitumor effect of chemotherapy and immunotherapy in syngeneic brain tumor models in mice Cancer Research. 70: 3825-3825. DOI: 10.1158/1538-7445.Am10-3825 |
0.455 |
|
| 2010 |
Candolfi M, Curtin JF, Yagiz K, Assi H, Wibowo M, Ahlzadeh G, Foulad D, Kroeger KM, Tesarfreund M, Alden A, Liu C, Dunn R, Lowenstein P, Castro MG. Abstract 1909: B cells present tumor antigen and mediate anti-tumor immunity induced by a combined immune-stimulatory/conditional cytotoxic therapy for glioblastoma Cancer Research. 70: 1909-1909. DOI: 10.1158/1538-7445.Am10-1909 |
0.388 |
|
| 2009 |
Candolfi M, Kroeger KM, Muhammad AK, Yagiz K, Farrokhi C, Pechnick RN, Lowenstein PR, Castro MG. Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Current Gene Therapy. 9: 409-21. PMID 19860655 DOI: 10.2174/156652309789753301 |
0.414 |
|
| 2009 |
Ghulam Muhammad AK, Candolfi M, King GD, Yagiz K, Foulad D, Mineharu Y, Kroeger KM, Treuer KA, Nichols WS, Sanderson NS, Yang J, Khayznikov M, Van Rooijen N, Lowenstein PR, Castro MG. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6113-27. PMID 19789315 DOI: 10.1158/1078-0432.Ccr-09-1087 |
0.44 |
|
| 2009 |
Candolfi M, Yagiz K, Foulad D, Alzadeh GE, Tesarfreund M, Muhammad AK, Puntel M, Kroeger KM, Liu C, Lee S, Curtin JF, King GD, Lerner J, Sato K, Mineharu Y, et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4401-14. PMID 19570774 DOI: 10.1158/1078-0432.Ccr-09-0155 |
0.337 |
|
| 2009 |
Yagiz K, Rittling SR. Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation. Experimental Cell Research. 315: 2442-52. PMID 19427849 DOI: 10.1016/J.Yexcr.2009.05.002 |
0.333 |
|
| 2009 |
Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, Muhammad AK, Clark MC, Arditi M, Comin-Anduix B, Ribas A, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. Plos Medicine. 6: e10. PMID 19143470 DOI: 10.1371/Journal.Pmed.1000010 |
0.462 |
|
| 2009 |
Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, Muhammad AKMG, Clark MC, Arditi M, Comin-Anduix B, Ribas A, et al. HMGB1 Is Released into the Supernatant of GL26, LLc1, GL261, and B16-F10 Tumor Cell Lines in Response to Treatment with Ad-TK (+GCV), Irradiation, or Temozolomide Plos Medicine. DOI: 10.1371/Journal.Pmed.1000010.G009 |
0.335 |
|
| 2008 |
Yagiz K, Snyder PW, Morré DJ, Morré DM. Cell size increased in tissues from transgenic mice overexpressing a cell surface growth-related and cancer-specific hydroquinone oxidase, tNOX, with protein disulfide-thiol interchange activity. Journal of Cellular Biochemistry. 105: 1437-42. PMID 18980249 DOI: 10.1002/Jcb.21962 |
0.567 |
|
| 2007 |
Morré DJ, Chueh PJ, Yagiz K, Balicki A, Kim C, Morré DM. ECTO-NOX target for the anticancer isoflavene phenoxodiol. Oncology Research. 16: 299-312. PMID 17518268 DOI: 10.3727/000000006783980973 |
0.594 |
|
| 2007 |
Yagiz K, Wu LY, Kuntz CP, Morré DJ, Morré DM. Mouse embryonic fibroblast cells from transgenic mice overexpressing tNOX exhibit an altered growth and drug response phenotype Journal of Cellular Biochemistry. 101: 295-306. PMID 17115410 DOI: 10.1002/Jcb.21184 |
0.604 |
|
| 2006 |
Yagiz K, Morré DJ, Morré DM. Transgenic mouse line overexpressing the cancer-specific tNOX protein has an enhanced growth and acquired drug-response phenotype. The Journal of Nutritional Biochemistry. 17: 750-9. PMID 16517149 DOI: 10.1016/J.Jnutbio.2005.12.006 |
0.586 |
|
| 2004 |
Zhou Q, Zhu Y, Chiang H, Yagiz K, Morre DJ, Morre DM, Janle E, Kissinger PT. Identification of the major vanilloid component in Capsicum extract by HPLC-EC and HPLC-MS. Phytochemical Analysis : Pca. 15: 117-20. PMID 15116943 DOI: 10.1002/Pca.754 |
0.469 |
|
| 1998 |
Yantiri F, Morré DJ, Yagiz K, Barogi S, Wang S, Chueh PJ, Cho N, Sedlak D, Morré DM. Capsaicin-responsive NADH oxidase activities from urine of cancer patients. Archives of Biochemistry and Biophysics. 358: 336-42. PMID 9784248 DOI: 10.1006/Abbi.1998.0877 |
0.534 |
|
| Show low-probability matches. |